Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro

Robert Vince, Mei Hua, Jay Brownell, Susan Daluge, Fangchen Lee, William M. Shannon, George C. Lavelle, Jeanine Qualls, Owen S. Weislow, Rebecca Kiser, Peter G. Canonico, Robert H. Schultz, V. L. Narayanan, Joseph G. Mayo, Robert H. Shoemaker, Michael R. Boyd

Research output: Contribution to journalArticlepeer-review

210 Scopus citations

Abstract

Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.

Original languageEnglish (US)
Pages (from-to)1046-1053
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume156
Issue number2
DOIs
StatePublished - Oct 31 1988

Bibliographical note

Funding Information:
This work was supported by NIH grant R01 CA23263, NCl contract NO1-CA-74102, and USAMRIID contract DAMD17-86-C-6013.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro'. Together they form a unique fingerprint.

Cite this